Drugs / FCX-013
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03740724 | Dec 2019 → Sep 2020 | localized scleroderma | Castle Creek Biosciences, LLC. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FCX-013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03740724 ↗ |
| Modality | Cell therapy | “FCX-013 is a genetically modified cell product obtained from the subject's own skin cells (autologous fibroblasts).” NCT03740724 ↗ |
| Route | Other | “FCX-013 cell suspension is injected intradermally.” NCT03740724 ↗ |
| Target | MMP1 | “The first component is FCX-013, an autologous genetically modified human dermal fibroblast (GM-HDFs) cell product that is genetically modified with a lentiviral vector (LV) to...” NCT03740724 ↗ |